Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018226769 - 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS

Publication Number WO/2018/226769
Publication Date 13.12.2018
International Application No. PCT/US2018/036167
International Filing Date 05.06.2018
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 491/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/5517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/22 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
22Anxiolytics
A61P 25/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
20Hypnotics; Sedatives
CPC
A61P 15/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
08for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 15/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
15Drugs for genital or sexual disorders
10for impotence
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
20Hypnotics; Sedatives
A61P 25/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
22Anxiolytics
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
Applicants
  • BLACKTHORN THERAPEUTICS, INC. [US]/[US]
Inventors
  • TIERNEY, Jason
  • HARDICK, David
  • URBANO, Mariangela
  • JONES, Robert, M.
  • BRANDT, Gary
  • KNIGHT, Chris
Agents
  • COOPER, Michael, P.
  • OBEIDAT, Baha, A.
  • KUMABE, Blake, K.
  • SOLTANI, Bobby, B.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • ROTH, Carol, J.
  • EIDT, Chandra, E.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • ABRAMONTE, Frank
  • HAN, Hai
  • TALBERT, Hayley, J.
  • WHITE, James, A. D.
  • BARRETT, Jared, M.
  • PEPE, Jeffrey, C.
  • DANLEY, Jeffrey, E.
  • SAKOI, Jeffrey, M.
  • BAUNACH, Jeremiah, J.
  • KARLEN, John, R.
  • MORGAN, John, A.
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • LINFORD, Lorraine
  • RUSYN, Paul
  • LIN, Qing
  • HALLER, Rachel, A.
  • IANNUCCI, Robert
  • KOVELMAN, Robert, L.
  • WEBB, Samuel, E.
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • ABEDI, Syed
  • SATAGAJ, Thomas, J.
  • BOLLER, Timothy, L.
  • LIGON, Toby, J.
  • FERRON, William, O., Jr.
  • ZENTZ, Bradley, J.
  • GERTZ, Glenda, A.
  • SHEWMAKE, Thomas, A.
  • CANTRELL, Tyler, C.
Priority Data
62/515,47305.06.2017US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS FOR TREATING NEUROPSYCHOLOGICAL DISORDERS
(FR) DÉRIVÉS DE 1-(2-AZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZÉPINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR V1A POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHOLOGIQUES
Abstract
(EN)
Compounds of Formula (I) that antagonize vasopressin receptors, particularly the Via receptor. The compounds are useful for treating e.g. neuropsychological disorders, such as e.g. anxiety, depression and schizophrenia. Preferred compounds are e.g. 1-(2-azaspiro[3.3]heptan-6-yl)-5,6- dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives.
(FR)
La présente invention concerne des composés de formule (I) qui ont un effet antagoniste sur les récepteurs de la vasopressine, en particulier le récepteur V1a. Les composés sont utiles pour traiter, par exemple, des troubles neuropsychologiques, tels que l'anxiété, la dépression et la schizophrénie. Les composés préférés selon l'invention, sont par exemple des dérivés de 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazépine.
Also published as
Latest bibliographic data on file with the International Bureau